Siozopoulou Vasiliki, Domen Andreas, Zwaenepoel Karen, Van Beeck Annelies, Smits Evelien, Pauwels Patrick, Marcq Elly
Department of Pathology, Antwerp University Hospital, 2650 Edegem, Belgium.
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, 2610 Wilrijk, Belgium.
Cancers (Basel). 2021 Jan 19;13(2):360. doi: 10.3390/cancers13020360.
Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. Immune checkpoint inhibitors (ICIs) have drawn a lot of attention last years because of their promising response rates and their durable effects. ICIs are currently widely used in the daily routine practice for the treatment of a different malignancies, such as melanoma, Hodgkin lymphoma, and non-small cell lung carcinoma. Still, ICIs are not included in the standard treatment protocols of the different sarcoma types. However, a plethora of clinical trials investigates the clinical benefit of ICIs in sarcomas. There is clear need to develop predictive biomarkers to determine which sarcoma patients are most likely to benefit from immune checkpoint blockade. This review will focus on (i) the clinical trial results on the use of ICIs in different sarcoma types; and on (ii) possible biomarkers predictive for the effectiveness of these drugs in sarcomas.
软组织和骨肉瘤是一组非常异质性的肿瘤，有许多亚型，其诊断和治疗仍然是一项非常具有挑战性的任务。除此之外，治疗选择有限，侵袭性肉瘤的预后仍然很差。免疫检查点抑制剂（ICIs）在过去几年中备受关注，因为它们有令人鼓舞的缓解率和持久疗效。ICIs目前广泛应用于日常临床实践中，用于治疗不同的恶性肿瘤，如黑色素瘤、霍奇金淋巴瘤和非小细胞肺癌。然而，ICIs并未纳入不同类型肉瘤的标准治疗方案中。尽管如此，大量临床试验正在研究ICIs在肉瘤中的临床益处。显然需要开发预测性生物标志物，以确定哪些肉瘤患者最有可能从免疫检查点阻断治疗中获益。本综述将聚焦于：（i）ICIs在不同类型肉瘤中应用的临床试验结果；以及（ii）可能预测这些药物在肉瘤中有效性的生物标志物。
